COVID-19 News And Beyond
Date & Time:
August 19, 12:00 PM EDT
Webinar: Details provided upon RSVP approval
About the Event:
Due to Covid-19, Broadway set designer, Edward Pierce, was on a ventilator for 46 days. His family agreed to participate in compassionate use treatment of Pluristem’s regenerative cell therapy. Just a few weeks later, “I was itching to get out of there.” He said. (Read Mr. Pierce’s full story and watch a video interview with him, his wife and his physician.) Pluristem’s compassionate use programs in severe Covid-19 patients resulted in a remarkable 87.5% survival rate after 28-day follow up and the company is now running a Phase II clinical trial in severe Covid-19 patients with ARDS in the U.S.
But Pluristem’s story is much more than Covid-19. In the coming year, the company will be delivering significant news on studies for a range of conditions.
- Pluristem plans to complete enrollment for a Phase II study of PLX-PAD for Covid-19 patients with ARDS at several sites in the United States and have top line results by the end of Q4 2020
- Pluristem expects to announce top line interim data analysis results during Q4 2020 for a global Phase III Study of PLX-PAD for use in Critical Limb Ischemia
- Pluristem is enrolling patients for a Phase III Muscle Regeneration Study following hip fracture and expect to have top line results Q3 2021
Please join our Webinar to hear from Pluristem CEO & president, Yaky Yanay as he talks about all the opportunities that lie ahead for the company, including its role in helping people recover from Covid-19.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.